TGFBI and hepatocellular adenoma: For TGFBI, which was inadvertently missed in the targeted proteomic assay, its plasma levels determined by ELISA did not significantly differ between the non-HCA and HCA groups within cohorts 1 and 2 (Fig 4), and the total study cohort (S7 Table).